194 related articles for article (PubMed ID: 26563350)
1. Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment.
Baxa J; Matouskova T; Krakorova G; Schmidt B; Flohr T; Sedlmair M; Bejcek J; Ferda J
Eur Radiol; 2016 Aug; 26(8):2828-36. PubMed ID: 26563350
[TBL] [Abstract][Full Text] [Related]
2. Dual-phase dual-energy CT in patients with lung cancer: assessment of the additional value of iodine quantification in lymph node therapy response.
Baxa J; Vondráková A; Matoušková T; Růžičková O; Schmidt B; Flohr T; Sedlmair M; Ferda J
Eur Radiol; 2014 Aug; 24(8):1981-8. PubMed ID: 24895031
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Iodine Quantification and FDG Uptake in Early Therapy Response Assessment of Non-small Cell Lung Cancer: Possible Benefit of Dual-energy CT Scan as an Integral Part of PET/CT Examination.
Baxa J; Ludvik J; Sedlmair M; Flohr T; Schmidt B; Hošek P; Pesek M; Svatoň M; Ferda J
Anticancer Res; 2020 Jun; 40(6):3459-3468. PubMed ID: 32487645
[TBL] [Abstract][Full Text] [Related]
4. Iodine quantification to characterize primary lesions, metastatic and non-metastatic lymph nodes in lung cancers by dual energy computed tomography: An initial experience.
Li X; Meng X; Ye Z
Eur J Radiol; 2016 Jun; 85(6):1219-23. PubMed ID: 27161073
[TBL] [Abstract][Full Text] [Related]
5. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
6. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
[TBL] [Abstract][Full Text] [Related]
7. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
8. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Lind JS; Meijerink MR; Dingemans AM; van Kuijk C; Ollers MC; de Ruysscher D; Postmus PE; Smit EF
Eur Radiol; 2010 Dec; 20(12):2890-8. PubMed ID: 20625738
[TBL] [Abstract][Full Text] [Related]
9. A comparative analysis of dual-phase dual-energy CT and FDG-PET/CT for the prediction of histopathological invasiveness of non-small cell lung cancer.
Ito R; Iwano S; Shimamoto H; Umakoshi H; Kawaguchi K; Ito S; Kato K; Naganawa S
Eur J Radiol; 2017 Oct; 95():186-191. PubMed ID: 28987666
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
11. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
12. "Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study.
Pezzuto A; Stumbo L; Russano M; Crucitti P; Scarlata S; Caricato M; Tonini G
Recent Pat Anticancer Drug Discov; 2015; 10(3):342-51. PubMed ID: 26246248
[TBL] [Abstract][Full Text] [Related]
13. Tumour response in non-small-cell lung cancer patients treated with chemoradiotherapy - Can spectral CT predict recurrence?
Fehrenbach U; Feldhaus F; Kahn J; Böning G; Maurer MH; Renz D; Frost N; Streitparth F
J Med Imaging Radiat Oncol; 2019 Oct; 63(5):641-649. PubMed ID: 31282130
[TBL] [Abstract][Full Text] [Related]
14. Endobronchial ultrasonography for positron emission tomography and computed tomography-negative lymph node staging in non-small cell lung cancer.
Shingyoji M; Nakajima T; Yoshino M; Yoshida Y; Ashinuma H; Itakura M; Tatsumi K; Iizasa T
Ann Thorac Surg; 2014 Nov; 98(5):1762-7. PubMed ID: 25149044
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
[TBL] [Abstract][Full Text] [Related]
16. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
[TBL] [Abstract][Full Text] [Related]
17. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
[TBL] [Abstract][Full Text] [Related]
18. [Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer].
Li M; Wu N; Liang Y; Zheng R; Liu Y; Zhang WJ; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):288-92. PubMed ID: 19615286
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA
J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma.
Hong SR; Hur J; Moon YW; Han K; Chang S; Kim JY; Im DJ; Suh YJ; Hong YJ; Lee HJ; Kim YJ; Choi BW
Eur J Radiol; 2018 Apr; 101():118-123. PubMed ID: 29571784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
